Brief: Ampio Pharmaceuticals' Study Shows Ampion Inhibits Key Inflammatory Pathway In COVID-19 And Lupus Nephritis
06/04/2021 14:19
April 6 (Reuters) - Ampio Pharmaceuticals Inc AMPE.A :
* AMPIO PHARMACEUTICALS' STUDY SHOWS AMPION INHIBITS A KEY
INFLAMMATORY PATHWAY IN COVID-19 AND LUPUS NEPHRITIS
* AMPIO PHARMACEUTICALS INC - AMPION REDUCED CXCL10 UP TO 92
PERCENT COMPARED TO A SALINE SOLUTION
Source text for Eikon: ID:nPnlwLM5a
Further company coverage: AMPE.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Ampio Pharmaceuticals
See all newsBrief: Ampio Announces Voluntary Delisting And SEC Deregistration
Brief: Ampio Provides Update On Results From Pre-IND Enabling Studies
Brief: Ampio Selects Ascendia Pharmaceuticals, Inc. To Provide CDMO Services To Support Clinical Development Of OA-201
Brief: Ampio Pharmaceuticals Announces Reverse Stock Split
Brief: Ampio Pharmaceuticals Inc - Holds Approximately $1.25 Million In A Deposit Account At Silicon Valley Bank